企業プロフィール
Fennec Pharmaceuticals Inc. 株価・ニュース・カタリスト
- ティッカー:
- FENC
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
11.83 USD (+0.94%)
終値
最終更新: 2026年8月17日
347M USD
時価総額
株価変動の要因
As of Aug 17, 2026, FENC closed up 0.94% at $11.83. No new same-company headline was identified in the current news window.
企業概要
Ototoxicity Prevention Company
Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy.
Pediatric Commercial Foundation
PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through an oncology sales organization and the Fennec HEARS patient-services hub.
Expansion into Older Patients
Investigator-sponsored studies are evaluating PEDMARK in adolescent, young adult, and adult patients receiving cisplatin for head and neck, testicular, cervical, and other cancers.
今後のカタリスト
- Clinical data from investigator-sponsored PEDMARK studies in additional age groups and tumor types are expected to define potential expansion opportunities.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。